Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | BioNTech SE | 158 |
| 2 | Merck Sharp & Dohme LLC | 111 |
| 3 | Kao Corp | 101 |
| 4 | Lipocine Inc | 92 |
| 5 | NOF Corp | 90 |
| 6 | Kimberly Clark Worldwide Inc | 86 |
| 7 | Lion Corp | 85 |
| 8 | Harvard University | 76 |
| 9 | Fujifilm Corp | 72 |
| 10 | Elan Pharmaceuticals LLC | 65 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 4,656 |
| 2 | A61P | Therapeutic activity (drug indications) | 3,118 |
| 3 | C12N | Microorganisms, enzymes | 1,818 |
| 4 | A61Q | Cosmetics, personal care | 1,039 |
| 5 | C07K | Peptides | 775 |
| 6 | C07D | Heterocyclic compounds | 574 |
| 7 | C07C | Acyclic and carbocyclic compounds | 508 |
| 8 | C07J | 377 | |
| 9 | G01N | Investigating / analysing materials | 329 |
| 10 | C12Y | Enzyme nomenclature (EC numbers) | 282 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Preparation method of dihydrocholesterol and cholestanone | 2009 | ANHUI CHEN-BRIGHT BIOENGINEERING CO., LTD. | 3 |
| Method for preparing dihydrocholesterol and cholestanone | 2011 | ANHUI CHEN-BRIGHT BIOENGINEERING CO., LTD. | 1 |
| USE OF DIHYDROCHOLESTEROL | 2017 | Nestec SA | 0 |
| USE OF DIHYDROCHOLESTEROL | 2016 | Nestec SA | 0 |
| Method for preparing dihydrocholesterol and cholestanone | 2013 | ANHUI CHEN-BRIGHT BIOENGINEERING CO., LTD. | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Cholesterol and Lipid Metabolism | 9 |
| 2 | Lipoproteins and Cardiovascular Health | 3 |
| 3 | Analytical Chemistry and Chromatography | 1 |
| 4 | Analytical Methods in Pharmaceuticals | 1 |
| 5 | Diet, Metabolism, and Disease | 1 |
| 6 | Drug Transport and Resistance Mechanisms | 1 |
| 7 | Groundwater and Isotope Geochemistry | 1 |
| 8 | Helicobacter pylori-related gastroenterology studies | 1 |
| 9 | Microbial infections and disease research | 1 |
| 10 | Microplastics and Plastic Pollution | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Helena Gylling | University of Eastern Finland | 18 |
| 2 | Antonio Federico | University of Siena | 12 |
| 3 | Ingemar Björkhem | Karolinska Institutet | 12 |
| 4 | Tatu A. Miettinen | University of Helsinki | 9 |
| 5 | Gerald Salen | United States Department of Veterans Affairs | 9 |
| 6 | Aad Verrips | Canisius-Wilhelmina Ziekenhuis | 8 |
| 7 | Dieter Lütjohann | University Hospital Bonn | 8 |
| 8 | Andrea E. DeBarber | Oregon Health & Science University | 7 |
| 9 | Andrea Mignarri | University of Siena | 6 |
| 10 | Elisabeth Norin | Karolinska Institutet | 6 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| The origin of faeces by means of biomarker detection | 2002 | 405 | Toxic Organic Pollutants Impact |
| Cholesterol Metabolism by Uncultured Human Gut Bacteria Influences Host Cholesterol Level | 2020 | 312 | Gut microbiota and health |
| Microflora‐associated characteristics in faeces from allergic and nonallergic infants | 2000 | 260 | Asthma and respiratory diseases |
| Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study | 1998 | 257 | Lipoproteins and Cardiovascular Health |
| Determination of endocrine-disrupting compounds in environmental samples using gas and liquid chromatography with mass spectrometry | 2002 | 240 | Pharmaceutical and Antibiotic Environmental Impacts |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical composition and molecular identity of Cholestan-3-ol?
How extensive is the patent and research coverage for Cholestan-3-ol?
Which organizations hold the most patents involving Cholestan-3-ol?
Who are the leading academic researchers publishing on Cholestan-3-ol?
What are the primary technological and research domains associated with Cholestan-3-ol?